Results 131 to 140 of about 197,893,593 (292)

: "Meeting the Master of 'Being-In-Common' at the World Bookstore: A Review of Jean-Luc Nancy's On The Commerce of Thinking"

open access: yes, 2012
International audienceThis article examines how Jean-Luc Nancy betrays his own philosophy of "Mitsein" (being-in-common) in a recent new work.本篇論文評析哲學大師儂曦新書 ...
Solomon, Jon
core  

Las limitaciones de la paz.

open access: yesRevista de Estudios Sociales, 2003
The article tries to offer some reflections about the limitations of what is known as peace, it is focused on four points which have become common places about what could happen if the war ends: 1) peace will lower the violence's rates; 2) peace will ...
Juan Carlos Garzón.
doaj  

From “Belligerent” to “Organised Armed Group”: Understanding the Legal Justification of the Metamorphosis of the Designation of Non-State Groups in a Common Article 3 Conflict

open access: yesFundamina
The Geneva Conventions were negotiated at the diplomatic conference held in Geneva in 1949, making 2024 its seventy-fifth anniversary. The intentions of states at that time concerning the identification of a non-state party to an armed conflict not of an international character was for a non-state group to be identified as belligerent; however, in ...
openaire   +1 more source

Targeting the EpCAM‐AXL axis to overcome drug resistance in lung cancer

open access: yesMolecular Oncology, EarlyView.
Lung cancer cells often evade therapy by hijacking signaling pathways. We reveal that cleaved EpCAM (sEpCAM) stabilizes the oncogenic protein AXL, driving NF‐κB and STAT3‐mediated chemoresistance. This EpCAM‐AXL axis identifies a high‐risk patient subset with poor prognosis.
Alexa Guerrero‐Alba   +5 more
wiley   +1 more source

RETRACTED ARTICLE: Isolation and analysis of homoeologous genes encoding gibberellin 2-oxidase 3 isozymes in common wheat [PDF]

open access: yesJournal of Genetics, 2012
QIUFANG CHEN   +8 more
openaire   +1 more source

Characterization of therapeutic antibodies targeting lymphatic and vascular resistance factor for the treatment of hypervascularized and highly metastatic cancers

open access: yesMolecular Oncology, EarlyView.
LVRF (lymphatic and vascular resistance factor) is a VEGFA splice variant upregulated in response to anti‐angiogenic therapy that fosters tumor adaptation through enhanced vascularization, lymphangiogenesis, and metastatic dissemination. Targeting LVRF with fully human neutralizing antibodies disrupts these processes and limits resistant tumor growth ...
Marion David   +12 more
wiley   +1 more source

Christians for the Common Good Poster, Fall 2020

open access: yes, 2020
Poster advertising Fall 2020 Zoom meetings of Christians for the Common Good (CCG), a reading and discussion group co-founded by Will Cohen and Christian Krokus in ...
University of Scranton. Christians for the Common Good
core  

Reprogramming tumor cells with LCOR mRNA nanotherapy to enhance immunotherapy

open access: yesMolecular Oncology, EarlyView.
LCOR (Ligand‐dependent corepressor) mRNA encapsulated in polymeric nanoparticles restores LCOR activity in tumor cells, constraining aggressive tumor cell states and increasing tumor immunogenicity. This reprogramming makes tumor cells more vulnerable to T‐cell attack and enhances their response to immune‐checkpoint immunotherapy.
Gabriel Serra‐Mir   +9 more
wiley   +1 more source

Engineering IL‐4 resistant proinflammatory human myeloid cells for cancer immunotherapy

open access: yesMolecular Oncology, EarlyView.
We developed a scalable workflow to generate proinflammatory human myeloid cells. CRISPR/Cas9‐edited CD34+ hematopoietic stem and progenitor cells were expanded and differentiated with M‐CSF. Deletion of STAT6 or STAT6/NFKB1 enhanced macrophage proinflammatory gene expression and cytokine secretion in the presence of IL‐4 while maintaining antibody ...
Theresa Barberi, Alan D. Friedman
wiley   +1 more source

Home - About - Disclaimer - Privacy